Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research

Astellas Venture Management, a wholly-owned venture capital subsidiary of Astellas Pharma, and LabCentral, a launchpad for early-stage life-sciences startups, have announced their collaboration on the "Future Innovator Prize" formerly known as the Astellas Golden Ticket Competition.

The Future Innovator Prize offers entrepreneurial scientists or emerging biotechnology start-ups one-year usage of LabCentral’s lab facility in Cambridge, MA, as well as access to Astellas’ research and development (R&D) capabilities and business leaders.

Astellas is offering up to two Future Innovator Prizes for pioneering scientists with innovative research that complements Astellas’ areas of interest that fit with the Astellas Focus Area Approach and pipeline, including oncology, immunology, neuroscience including neuromuscular and sensory disorders.

Companies awarded an Astellas Future Innovator Prize will gain one year's priority admission or renewal to LabCentral’s state-of-the-art laboratory as well as access to Astellas' R&D scientists and leaders.

Time for submitting applications for the competition is from Wednesday August 18, 2021 to Monday September 20, 2021.

Entrepreneurial scientists, emerging life-science or biotech start-ups are encouraged to apply and can learn more about the opportunity at http://www.astellasfutureinnovator.com.